Dermal Abyss is a project between researchers from the Massachusetts Institute of Technology (MIT) and Harvard Medical School. They have developed three different biosensing tattoo inks that can change color in response to changing (high or low) blood sugar or glucose, pH and sodium levels in men, female or women patients. They monitored the random medical condition of the patients. They have replaced traditional tattoos inks with d-abyss biosensor (biosensitive) inks.
They can read the concentration of sodium, pH and glucose (of a diabetic patient) in the interstitial fluid of the skin and they provide alternative options to monitor health complications such as electrolyte imbalance, alkalosis, acidosis, diabetes and hypertension. The d-abyss biosensors (biosensitive inks) are less invasive. A gallery of some pictures, images and graphic designs were displayed on the right side.
Colors of these biosensors changes with respect to changes in the interstitial fluid. The color of the ink which monitors blood sugar or glucose levels turns into "brown" color from "blue" color as blood sugar levels increases. The pH biosensors ink changes from "purple" color to "pink" color.
These inks are very useful to those insulin based diabetes patients who require checking their blood sugar levels with a finger prick testing, an invasive procedure, between four to ten times daily. Researchers have done the preliminary evaluation and biosensitive tattoo color inks are under testing process. The leader of the project was Katia Canepa Vega, MIT's Media Lab.
A study done by researchers shows marked higher risk for heart failure among those early-stage prostate cancer male patients who have received androgen deprivation therapy (ADT). Researchers followed 7,637 men between 1998 and 2008 who are diagnosed with localized prostate cancer (cancer is contained within the prostate gland). Researchers have done 12 years follow up studies and 30 percent of them received androgen deprivation therapy (also known as androgen suppression therapy).
Their study shows 81 percent enhanced risk of heart failure among prostate cancer patients without cardiovascular diseases (CVD) at the start of the study and received androgen deprivation hormone therapy. Among men with cardiovascular disease (CVD) at the start of the study, the study results show 44 percent enhanced risk of arrhythmia (abnormal and irregular heart rate) and risk for likely development of conduction disorder of the heart (electrical impulses of the heart) by three times. The researchers factored other risk factors such as tobacco use, body mass index (BMI), prostate-specific antigen levels, hypertension or blood pressure (BP), diabetes or high blood sugar or glucose levels and cardiovascular diseases (CVD).
Researchers say localized prostate cancer patients should consider the effects of the androgen deprivation therapy (ADT) and they should discuss with their healthcare professionals. Patients should adjust their lifestyle to reduce risks and symptoms associated with cardiovascular diseases (CVD) if they want to undergo androgen deprivation therapy (ADT). The following table describes the survival rates with local or regional prostate cancer without any treatment.
Lead authors of the study were Reina Haque, PhD, MPH, research scientist II, Department of Research & Evaluation, Kaiser Permanente Southern California. The study findings were published on August 24, 2017, in the British Journal of Cancer. Title of the article was "Cardiovascular disease risk and androgen deprivation therapy (ADT) in patients with localized prostate cancer: a prospective cohort study."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.